Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

181. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer Full Text available with Trip Pro

and health-related quality of life (HRQoL) benefits were assessed using two self-administered questionnaires (the European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire-Core (EORTC QLQ-C30), and the 13-item EORTC QLQ-lung cancer-specific module) at enrolment and every 6 weeks until week 66, disease progression or death.Clinically meaningful mean improvements (≥10 point change from baseline) were observed in 10 domains, including global health status (GHS), role (...) Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK-positive non-small cell lung cancer. We describe patient-reported outcomes (PROs) from the NP28761 study.PROs

2018 ESMO open

182. Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer Full Text available with Trip Pro

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer This study was conducted to identify whether the presence of circulating tumor DNA (ctDNA) in plasma before treatment with EGFR-tyrosine kinase inhibitors (TKIs) is associated with clinical outcomes.Fifty-seven pairs of tissues and plasma samples were obtained from patients with NSCLC adenocarcinoma harboring activating (...) prior to disease progression.Quantitative testing can increase the sensitivity of the ctDNA detection test. Patients with detectable ctDNA had significantly shorter PFS after receiving EGFR-TKIs than those with undetectable ctDNA. Tumor burden may be associated with plasma ctDNA detection. A shorter PFS was associated with detection of ctDNA and extra-thoracic lymph node metastasis. Dynamic changes in the ctDNA level may help predict clinical outcomes.© 2018 The Authors. Thoracic Cancer published

2018 Thoracic cancer

183. Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report Full Text available with Trip Pro

Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report Squamous cancer (SqCC) of the lung has a poor prognosis. With the advent of immunotherapy, prognosis has tended to improve; however, pseudoprogression poses a challenge to the management of immunotherapy. Herein, we discuss the case of a 47-year-old heavy smoker with advanced SqCC. The patient had recurrent disease after initial successful control of the tumor by concurrent (...) for pseudoprogression. Our experience might be helpful to identify pseudoprogression for the clinical management of immunotherapy.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

184. Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer Full Text available with Trip Pro

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis.Targeted next-generation sequencing (NGS) mutation profiling (...) in PIK3CA, MET, and KRAS. Interestingly, we identified two patients with acquired mutations in the DNA mismatch repair gene POLE, which resulted in a dramatically increased tumor mutation burden, and might contribute to the poor response to crizotinib.Heterogeneous resistant mechanisms have been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes.© 2018 The Authors. Thoracic Cancer published by China

2018 Thoracic cancer

185. Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population (Abstract)

Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population To assess the performance of the Brock malignancy risk model for pulmonary nodules detected in routine clinical setting.In two academic centres in the Netherlands, we established a list of patients aged ≥40 years who received a chest CT scan between 2004 and 2012, resulting in 16 850 and 23 454 eligible subjects. Subsequent diagnosis of lung cancer until the end of 2014 was established (...) through linking with the National Cancer Registry. A nested case-control study was performed (ratio 1:3). Two observers used semiautomated software to annotate the nodules. The Brock model was separately validated on each data set using ROC analysis and compared with a solely size-based model.After the annotation process the final analysis included 177 malignant and 695 benign nodules for centre A, and 264 malignant and 710 benign nodules for centre B. The full Brock model resulted in areas under

2018 EvidenceUpdates

186. Lung cancer

Lung cancer Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) . Also read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

187. Palliative thoracic radiotherapy in lung cancer

% of all lung cancer diagnoses. 1 More than one-half of patients with NSCLC are diagnosed with locally advanced (stage III) and advanced (stage IV) disease. 2 Because palliative thoracic radiationtherapyplaysanimportantroleforthesepatients, the American Society for Radiation Oncology (ASTRO) published a clinical practice guideline on this topic in 2011. 3 The guideline addressed 3 key questions (KQs) related to palliative thoracic external beam radiation therapy (EBRT): (1) dose and fractionation (...) chemoradiation leads to survival andqualityoflifebenefitsinpoorprognosisstageIIInon-small-cell lung cancer: A randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2013;109:1467-1475. 12. StromHH,BremnesRM,SundstromSH,HelbekkmoN,AaseboU. Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial. J Thorac Oncol. 2014;9:825-833. 13. StromHH,BremnesRM,SundstromSH

2018 American Society for Radiation Oncology

188. Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19

the drug. Patients on the chemotherapy arm who showed progression were allowed to cross over to receive alectinib treatment. Upon progression on cross-over treatment with alectinib, patients were allowed to continue receiving alectinib beyond disease progression if he or she was benefitting from the drug. ALK: anaplastic lymphoma kinase; ECOG PS: Eastern Cooperative Oncology Group Performance Status; n: relevant subpopulation; N: number of randomized patients; NSCLC: non-small cell lung cancer; PFS (...) progression Side effects All outcomes in the category “side effects” Until 4 weeks after the last dose of the study medication; patients with continued alectinib treatment after disease progression are observed until 4 weeks after the last dose of alectinib AE: adverse event; EORTC: European Organisation for Research and Treatment of Cancer; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-LC13: Quality of Life Questionnaire-Lung Cancer 13; RCT: randomized controlled trial; SAE: serious adverse event

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

189. Osimertinib (lung cancer) - Addendum to Commission A17-20

, randomized study of AZD9291 (osimertinib) versus platinum-based doublet chemotherapy for patients with locally advanced or metastatic non- small cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumours harbour a T790M mutation within the epidermal growth factor receptor gene (AURA3): study D5160C00003; Zusatzanalysen [unpublished]. 2017. 4. Gemeinsamer Bundesausschuss. Anlage VI zum Abschnitt K der Arzneimittel (...) Osimertinib (lung cancer) - Addendum to Commission A17-20 1 Translation of addendum A17-47 Osimertinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-20 (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 September 2017 1.0 Commission: A17-47 Version: Status: IQWiG Reports – Commission No. A17-47

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

190. Atezolizumab (Tecentriq) for non?small cell lung cancer (NSCLC)

of life and orphan medicine process atezolizumab (Tecentriq ® ) is accepted for restricted use within NHS Scotland Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic non -small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) -positive tumour mutations should also have received targeted therapy before receiving atezolizumab. SMC (...) that is equivalent or lower. This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting. Vice Chairman Scottish Medicines Consortium 2 Indication As monotherapy for the treatment of adult patients with locally advanced or metastatic non -small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) -positive tumour mutations should also have received targeted therapy before

2018 Scottish Medicines Consortium

191. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

than 2% of people with non-small-cell lung cancer (NSCLC) have ROS1-positive advanced NSCLC. The ROS1 oncogene is thought to be found almost exclusively in non-squamous NSCLC, mainly in tumours with adenocarcinoma histology. The committee noted that the ROS1 oncogene was only recently discovered; so limited information is available on the natural history, patient characteristics and the clinical effectiveness of chemotherapy for tumours that are ROS1-positive. The clinical experts highlighted (...) ROS1-positive advanced non-small-cell lung cancer (TA529) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 26can induce durable tumour shrinkage and slow disease progression, particularly in previously treated ROS1-positive advanced NSCLC. In response to consultation, the company highlighted that its original submission included results from a UK clinical audit by the Royal Marsden and other small studies

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

192. Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases Full Text available with Trip Pro

Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM).Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who received WBRT plus TMZ (TMZ + WBRT) and 33 patients who received WBRT alone (WBRT (...) effects, no significant difference was observed. Thus, TMZ is safe and effective.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

193. Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma Full Text available with Trip Pro

Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma Y-Box Binding protein 1 (YBX-1) is known to be involved in various types of cancers. It's interactors also play major role in various cellular functions. Present work aimed to study the expression profile of the YBX-1 interactors during lung adenocarcinoma (LUAD). The differential expression analysis involved 57 genes from 95 lung adenocarcinoma samples, construction of gene network

2018 Journal of genomics

194. Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer Full Text available with Trip Pro

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer 30035160 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer. 124-125 10.18632/oncoscience.416 Seguin Laetitia L INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. Féral Chloé C INSERM, U1081, CNRS, UMR7284, Institute (...) for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. eng Editorial 2018 06 23 United States Oncoscience 101636666 2331-4737 KRAS galectin-3 integrin lung cancer macropinocytosis CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 03 2018 04 05 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035160 10.18632/oncoscience.416 416 PMC6049313 Cancer Immunol Res. 2017 Mar;5(3):182-190 28108630 Nat Cell Biol. 2014 May;16(5):457

2018 Oncoscience

195. hsa_circ_0000729, a potential prognostic biomarker in lung adenocarcinoma Full Text available with Trip Pro

hsa_circ_0000729, a potential prognostic biomarker in lung adenocarcinoma Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for cancer progression.We examined differentially expressed circRNAs in LUAD and paired normal tissues using downloaded (...) development. Larger area under the curve by receiver operating characteristic curve analysis of hsa_circ_0000792 and miR-375 (0.815 and 0.772, respectively) in LUAD indicated greater potential as biomarkers.We identified hsa_circ_0000792 as a potential LUAD biomarker; however, further studies are required to determine the mechanism of this circRNA in LUAD development.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

196. Feasibility of an eight‐week outpatient‐based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea Full Text available with Trip Pro

hospital setting. Patients with advanced lung cancer (non-small cell lung cancer IIIB-IV and small-cell lung cancer extensive disease) scheduled to undergo first-line cytotoxic chemotherapy underwent PR consisting of 60-minute sessions twice a week under the guidance and supervision of a physical therapist, for a total of eight weeks. Feasibility was assessed based on completion of the PR program. In total, 12 patients (median age 68 years) were enrolled; 11 (91.7%) were male with a history of smoking (...) Feasibility of an eight‐week outpatient‐based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea The scientific evidence supporting pulmonary rehabilitation (PR) for lung cancer patients undergoing cytotoxic chemotherapy is accumulating; however, the feasibility of outpatient-based PR in these patients has not yet been evaluated in Korea. We conducted an eight-week outpatient-based PR feasibility study in a tertiary referral

2018 Thoracic cancer

197. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer Full Text available with Trip Pro

Cell Death 1 Receptor IM Antineoplastic Agents, Immunological pharmacology therapeutic use B7-H1 Antigen antagonists & inhibitors Carcinoma, Non-Small-Cell Lung drug therapy genetics Clinical Trials as Topic DNA Damage drug effects Humans Immunotherapy Lung Neoplasms drug therapy genetics Programmed Cell Death 1 Receptor antagonists & inhibitors Signal Transduction drug effects 2018 05 15 2018 05 15 2018 6 23 6 0 2018 6 23 6 0 2018 6 23 6 0 ppublish 29932513 10.1111/1759-7714.12785 PMC6068455 N (...) DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer 29932513 2019 03 25 2019 03 25 1759-7714 9 8 2018 08 Thoracic cancer Thorac Cancer DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. 901-903 10.1111/1759-7714.12785 Zhu Zhongling Z Department of Clinical Pharmacology, Tianjin

2018 Thoracic cancer

198. Survival rates after lobectomy versus sublobar resection for early‐stage right middle lobe non‐small cell lung cancer Full Text available with Trip Pro

Survival rates after lobectomy versus sublobar resection for early‐stage right middle lobe non‐small cell lung cancer Lung cancer in the right middle lobe has a poorer prognosis than tumors located in other lobes. The optimal surgical procedure for early-stage non-small cell lung cancer (NSCLC) in the right middle lobe has not yet been elucidated. The aim of this study was to compare survival rates after lobectomy and sublobar resection for early-stage right middle lobe NSCLC.Patients who (...) underwent lobectomy or sublobar resection for stage IA right middle lobe NSCLC tumors ≤ 2 cm between 2004 and 2014 were identified from the Surveillance, Epidemiology and End Results database of 18 registries. Cox regression model analysis was used to evaluate the prognostic factors. The lung cancer-specific survival (LCSS) and overall survival (OS) rates between the two groups were compared.A total of 861 patients met our criteria, including 662 (76.9%) patients who underwent lobectomy and 199 (23.1

2018 Thoracic cancer

199. Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors Full Text available with Trip Pro

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors Although patients with EGFR-mutant non-small-cell lung cancer (NSCLC) benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility of EGFR-TKI therapy (...) survival was 23 months (range 15-64).The longer disease control observed in our patients suggests that continuation of EGFR-TKI beyond focal progression associated to microwave ablation is an efficacious therapeutic strategy.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

200. Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer Full Text available with Trip Pro

Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer Platinum-based chemotherapy is the standard first-line treatment for patients with advanced pan-negative non-squamous (non-Sq) non-small cell lung cancer (NSCLC). However, it is unknown which chemotherapy regimen confers the greatest benefit in such patients. This study explored which chemotherapy regimens were advantageous in non-Sq NSCLC (...) = 0.001) in a final multivariate Cox regression model.A PP regimen tends to be more beneficial than an NPP regimen for patients with pan-negative advanced non-Sq NSCLC. Smoking status may be a valuable predictor for the selection of a chemotherapy regimen in such patients.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer